Your session is about to expire
← Back to Search
Monoclonal Antibodies
Tildrakizumab for Psoriasis
Phase 4
Recruiting
Led By Raymond Cho, MD, PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age or older
Patients with moderate-severe psoriasis or > 5% body surface area affected.
Must not have
Taking systemic immunosuppressives in the last 4 weeks
Active systemic malignancy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months
Awards & highlights
All Individual Drugs Already Approved
Drug Has Already Been Approved
Pivotal Trial
No Placebo-Only Group
Summary
This trial will study how well an experimental drug works in people with psoriasis.
Who is the study for?
This trial is for adults over 18 with moderate to severe psoriasis, affecting more than 5% of their body. It's not suitable for those on systemic immunosuppressives in the last month, pregnant or breastfeeding individuals, people with severe immune deficiencies, active tuberculosis or other serious infections, and anyone with an active systemic cancer.
What is being tested?
The study is testing Tildrakizumab injections to see how they affect skin and blood immune cells in psoriasis patients. The goal is to understand the changes in immune function after starting treatment with this IL23 blocker.
What are the potential side effects?
Tildrakizumab may cause side effects such as upper respiratory infections, headache, fatigue, injection site reactions like pain or swelling, and possibly allergic reactions. Long-term use might increase infection risk due to its effect on the immune system.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
My psoriasis is severe or covers more than 5% of my body.
Select...
My psoriasis covers more than 5% of my body.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not taken any immunosuppressive drugs in the last 4 weeks.
Select...
I have an active cancer that is affecting my whole body.
Select...
I have a severe immune system problem.
Select...
I do not have tuberculosis or any serious infection.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Psoriasis Area and Severity Index (PASI) Score at baseline and 3 months of treatment
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tildrakizumab treatmentExperimental Treatment1 Intervention
Biological/vaccine: tildrakizumab
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,586 Previous Clinical Trials
15,084,245 Total Patients Enrolled
Sun Pharmaceutical Industries LimitedIndustry Sponsor
69 Previous Clinical Trials
13,785 Total Patients Enrolled
Raymond Cho, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
4 Previous Clinical Trials
57 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not taken any immunosuppressive drugs in the last 4 weeks.I have an active cancer that is affecting my whole body.I have a severe immune system problem.I am 18 years old or older.My psoriasis is severe or covers more than 5% of my body.I do not have tuberculosis or any serious infection.My psoriasis covers more than 5% of my body.
Research Study Groups:
This trial has the following groups:- Group 1: Tildrakizumab treatment
Awards:
This trial has 4 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger